Szpital Wojewodzki Im. Mikolaja Kopernika W Koszalinie

At Szpital Wojewodzki Im. Mikolaja Kopernika W Koszalinie, most trials focus on neoplasms, especially advanced and metastatic cancers. The research spans breast cancer, lung cancer, gastric and gastroesophageal cancer, and other solid tumors, with studies aimed at testing new treatments, improving disease control, and measuring treatment effectiveness.

• Breast cancer, including hormone receptor-positive, HER2-negative, HER2-low, and triple-negative disease
• Non-small cell lung cancer and small cell lung cancer, with attention to advanced and unresectable disease
• Gastric, gastroesophageal junction, and esophageal cancer studies exploring new combinations and targeted approaches

Many of these trials are designed to assess whether newer immunotherapy, targeted therapy, or combination strategies can improve survival and slow cancer progression.

A major part of the site’s research portfolio covers male urogenital diseases and related cancers, including prostate cancer, bladder cancer, and urothelial carcinoma. These studies often look for better ways to control advanced disease, reduce recurrence, and support patients whose cancer has spread or become resistant to standard care.

• Prostate cancer, including metastatic castration-resistant and castration-sensitive disease
• Bladder cancer and muscle-invasive urothelial carcinoma
• Metastatic urothelial cancer research focused on improving outcomes and extending survival

The work in this area emphasizes testing new treatment options and evaluating how well they delay progression or improve overall response.

The site also has a strong focus on immunotherapy and precision oncology, with trials exploring biomarkers such as PD-L1, HER2, FGFR2b, KRAS G12C, and PIK3CA. These studies aim to match treatment more closely to tumor features and improve the chance of benefit for selected patients.

• Biomarker-driven breast cancer, lung cancer, and urothelial cancer studies
• Checkpoint inhibitor combinations designed to strengthen the immune response against cancer
• Targeted therapy research for tumors with specific genetic or molecular changes

This area reflects a growing effort to personalize cancer care by using tumor characteristics to guide treatment selection.

Additional trials at the Koszalin site cover renal cell carcinoma, hepatocellular carcinoma, colorectal cancer, head and neck squamous cell carcinoma, and other digestive system cancers. These studies are generally aimed at improving tumor control, evaluating new combinations, and finding more effective options for advanced disease.

• Renal cell carcinoma and other kidney cancer subtypes
• Colorectal, liver, and biliary tract cancer research
• Head and neck cancer trials focused on treatment after chemoradiation or in advanced disease

The research in these fields supports broader efforts to expand treatment choices for cancers that are often difficult to manage once they become advanced.

Beyond disease-specific oncology, the site contributes to studies addressing broader physiological phenomena and treatment-related challenges, including cancer cachexia, cancer-associated thrombosis, and therapy-related blood count problems. These trials help improve supportive care and the overall safety of cancer treatment.

• Cancer cachexia and nutrition-related complications
• Cancer-associated thrombosis and other treatment-related risks
• Blood and metabolic effects linked to cancer and its treatment

This work complements the oncology program by focusing on quality of life, complication prevention, and better treatment tolerance.